Published in Biomed Res Int on July 17, 2017
Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs--worldwide, 2000-2004. MMWR Morb Mortal Wkly Rep (2006) 7.90
Prevalence of and risk factors for resistance to second-line drugs in people with multidrug-resistant tuberculosis in eight countries: a prospective cohort study. Lancet (2012) 6.78
National survey of drug-resistant tuberculosis in China. N Engl J Med (2012) 6.28
Risk factors for multidrug resistant tuberculosis in Europe: a systematic review. Thorax (2005) 3.81
Tuberculosis burden in households of patients with multidrug-resistant and extensively drug-resistant tuberculosis: a retrospective cohort study. Lancet (2010) 3.32
Fluoroquinolones, tuberculosis, and resistance. Lancet Infect Dis (2003) 3.24
Molecular analysis of cross-resistance to capreomycin, kanamycin, amikacin, and viomycin in Mycobacterium tuberculosis. Antimicrob Agents Chemother (2005) 3.01
Overexpression of the chromosomally encoded aminoglycoside acetyltransferase eis confers kanamycin resistance in Mycobacterium tuberculosis. Proc Natl Acad Sci U S A (2009) 2.77
Detection of kanamycin-resistant Mycobacterium tuberculosis by identifying mutations in the 16S rRNA gene. J Clin Microbiol (1998) 2.28
A systematic review of gyrase mutations associated with fluoroquinolone-resistant Mycobacterium tuberculosis and a proposed gyrase numbering system. J Antimicrob Chemother (2012) 2.16
Emergence of increased resistance and extensively drug-resistant tuberculosis despite treatment adherence, South Africa. Emerg Infect Dis (2010) 2.14
Global control of tuberculosis: from extensively drug-resistant to untreatable tuberculosis. Lancet Respir Med (2014) 1.98
Transmission of drug-resistant tuberculosis among treated patients in Shanghai, China. J Infect Dis (2007) 1.36
Spoligotyping and drug resistance analysis of Mycobacterium tuberculosis strains from national survey in China. PLoS One (2012) 1.36
Structural insights into the quinolone resistance mechanism of Mycobacterium tuberculosis DNA gyrase. PLoS One (2010) 1.35
Emergence and treatment of multidrug resistant (MDR) and extensively drug-resistant (XDR) tuberculosis in South Africa. Infect Genet Evol (2011) 1.27
Rapid diagnosis of drug resistance to fluoroquinolones, amikacin, capreomycin, kanamycin and ethambutol using genotype MTBDRsl assay: a meta-analysis. PLoS One (2013) 1.25
First- and second-line drug resistance patterns among previously treated tuberculosis patients in India. Int J Tuberc Lung Dis (2010) 1.22
Association of mutation patterns in gyrA/B genes and ofloxacin resistance levels in Mycobacterium tuberculosis isolates from East China in 2009. BMC Infect Dis (2011) 1.10
Extensively drug-resistant tuberculosis, Taiwan. Emerg Infect Dis (2008) 1.08
Molecular characterization of multidrug- and extensively drug-resistant Mycobacterium tuberculosis strains in Jiangxi, China. J Clin Microbiol (2012) 1.06
Prevalence and molecular characterization of fluoroquinolone-resistant Mycobacterium tuberculosis isolates in China. Antimicrob Agents Chemother (2013) 1.01
Risk factors for acquisition of drug resistance during multidrug-resistant tuberculosis treatment, Arkhangelsk Oblast, Russia, 2005-2010. Emerg Infect Dis (2015) 0.86
Analysis of embCAB mutations associated with ethambutol resistance in multidrug-resistant mycobacterium tuberculosis isolates from China. Antimicrob Agents Chemother (2015) 0.82
Alternate efflux pump mechanism may contribute to drug resistance in extensively drug-resistant isolates of Mycobacterium tuberculosis. Int J Mycobacteriol (2016) 0.80
Acquisition of second-line drug resistance and extensive drug resistance during recent transmission of Mycobacterium tuberculosis in rural China. Clin Microbiol Infect (2015) 0.80
Prevalence and molecular characteristics of drug-resistant Mycobacterium tuberculosis in Beijing, China: 2006 versus 2012. BMC Microbiol (2016) 0.79
RNA expression analysis of efflux pump genes in clinical isolates of multidrug-resistant and extensively drug-resistant Mycobacterium tuberculosis in South Korea. Infect Genet Evol (2017) 0.78
Second-line anti-tuberculosis drug resistance and its genetic determinants in multidrug-resistant Mycobacterium tuberculosis clinical isolates. J Microbiol Immunol Infect (2015) 0.77
Resistance to Second-Line Antituberculosis Drugs and Delay in Drug Susceptibility Testing among Multidrug-Resistant Tuberculosis Patients in Shanghai. Biomed Res Int (2016) 0.75